Authors' objectives: Glioblastoma is a type of brain cancer that develops from cells that support nerve tissue. Glioblastoma is the most common type of brain cancer. After surgery or chemotherapy, this cancer often returns and most patients with glioblastoma do not survive for very long after their diagnosis. Nivolumab is a new antibody drug for the treatment of glioblastoma and is delivered straight into the bloodstream via a drip. It may stimulate the immune system to attack cancer cells. Some studies have suggested nivolumab may be helpful for people whose first treatment has failed and whose disease has spread. Another, larger study is now running and is aiming to find out how well nivolumab works and that it is safe to use. If nivolumab is licenced for use in the UK, it could be a new treatment option for patients with glioblastoma that may improve survival when current treatments have stopped working.

Project Status: Completed

Year Published: 2015

URL for published report: http://www.hsric.nihr.ac.uk/topics/nivolumab-for-recurrent-glioblastoma-second-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)